Fu­ji­film's CD­MO arm plots mas­sive $2B plant in the US for broad range of ther­a­peu­tics

Buoyed by in­ter­est from ma­jor Covid-19 vac­cine mak­ers for its vi­ral-vec­tor ca­pa­bil­i­ties, Fu­ji­film’s CD­MO arm has looked to rapid­ly build its US foot­print to meet de­mand. Now, just days af­ter un­veil­ing plans for a new HQ in the Boston area, Fu­ji­film is putting down a mas­sive down pay­ment on an­oth­er US site.

Fu­ji­film will spend $2 bil­lion by 2025 to build a large-scale cell cul­ture pro­duc­tion plant near one of its ex­ist­ing fa­cil­i­ties as the Japan­ese CD­MO looks to ex­pand and scale its US foot­print. The newest plant will help boost Fu­ji­film Diosynth Biotech­nolo­gies’ cu­mu­la­tive growth by 20% by March 2026, the com­pa­ny said.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.